On Jan. 11, 2021, TheNew York Times posted an article about the virtues of fecal immunochemical testing relative to colonoscopy. The story, “A Colonoscopy Alternative Comes Home” [https://www.nytimes.com/ 2021/ 01/ 11/ health/ colonoscopy-health-home-testing.html] depicted colonoscopy as a comparatively risky procedure with few advantages over less invasive methods of testing for colorectal cancer. It also offered the speculation that financial factors— namely, greater reimbursement for endoscopy—was behind the general preference of gastroenterologists for colonoscopy over stool tests.
Trending
- Lessons from Sam Holliday, CEO and Co-Founder of Oshi Health, on Building a Virtual GI Center of Excellence (Pear Healthcare Playbook)
- UnitedHealth Adopts Aggressive Approach to Recover Ransomware Attack Loans (The HIPAA Journal)
- Cardinal Health’s acquisition of GI Alliance: What is means for the industry (Becker’s GI & Endoscopy)
- Why SIBO is often misdiagnosed as IBS [PODCAST] (KevinMD)
- Pfizer to discontinue its GLP-1 pill for obesity due to liver toxicity (STAT)
- The AI Paradigm: A Doctor’s Perspective (The Second Opinion)
- Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial (PRNewswire)
- Gas-sensing capsule takes another big step from lab to commercialization (EurekAlert!)
